A Phase I Safety Study of NVG-291 in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

June 4, 2023

Study Completion Date

July 3, 2023

Conditions

Spinal Cord Injury

Interventions

DRUG

NVG-291

NVG-291 is a drug injected under the skin (subcutaneous).

OTHER

Placebo

Salt water is being used as a placebo and will be injected under the skin (subcutaneous).

Trial Locations (1)

Nucleus Networks, Melbourne